CX13-608

CX13-608 is an investigational proteasome inhibitor developed for the treatment of multiple myeloma, particularly in patients who have relapsed or are refractory after receiving standard therapies such as alkylating agents, anthracyclines, bortezomib, and immunomodulatory drugs (IMiDs). The drug is administered intravenously and has undergone Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in relapsed or refractory multiple myeloma patients. Phase 2 studies are ongoing to evaluate efficacy endpoints such as overall response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The mechanism of action involves inhibition of the proteasome pathway, which disrupts protein degradation processes critical for cancer cell survival[1][2][3][5].

Other names

CX13-608CX-13-608CX 13-608